Ergebnis der Suchanfrage nach B&ouml

Boehringer Ingelheim

New Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS)

Ingelheim, Germany (ots/PRNewswire) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS-Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce RLS-associated limb pain in patients with ...

United Internet AG

euro adhoc: United Internet AG / Release of a voting rights announcement according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim of a Europe-wide distribution

Further inquiry note: Branche: Telecommunications Services ISIN: DE0005089031 WKN: 508903 Index: Midcap Market Index, TecDAX, CDAX, HDAX, Prime All Share, Technologie All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Hamburg / free trade Börse Stuttgart / ...

OMV Aktiengesellschaft

OMV: Convocation of the Annual General Meeting

May 14, 2008, at 2:00 pm (CET), at the AUSTRIA CENTER VIENNA, in Bruno-Kreisky-Platz 1, 1220 Vienna, Austria Further inquiry note: OMV Investor Relations: Ana-Barbara Kuncic Tel. +43 1 40 440-21443; e-mail: investor.relations@omv.com Press: Bettina Gneisz-Al-Ani Tel. +43 1 40 440-21660; e-mail: bettina.gneisz@omv.com Thomas Huemer Tel. +43 1 40 440-21660; e-mail: thomas.huemer@omv.com Internet Homepage: ...

Boehringer Ingelheim

New Data Confirm Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Sleep Disturbance for People With Restless Legs Syndrome (RLS)

Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A. - Studies Demonstrate Positive and Rapid Impact of Pramipexole on the Core Symptoms of Restless Legs Syndrome and Sleep Disturbance A new study has shown that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce sleep ...

Vienna Insurance Group

Wiener Städtische Versicherung AG Vienna Insurance Group: Dividend / Share Repurchase

Further inquiry note: Mag. Barbara Hagen-Grötschnig Unternehmenskommunikation WIENER STÄDTISCHE Versicherung AG Vienna Insurance Group A-1010 Wien, Schottenring 30 Tel.: +43 (0)50 350-21027 Fax: +43 (0)50 350 99-21027 E-Mail: b.hagen@staedtische.co.at Branche: Insurance ISIN: AT0000908504 WKN: A0ET17 Index: WBI, ATX Prime, ATX Börsen: Prague Stock Exchange / stock ...

Boehringer Ingelheim

New Powerful Antihypertensive MicardisPlus(R) 80/25 (80mg telmisartan/25mg hydrochlorothiazide) Approved by EU Commission

Ingelheim, Germany (ots/PRNewswire) - - For Medical Media, Outside the US Only Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus(R) 80/25 in all 27 EU member states. It ...

Vienna Insurance Group

euro adhoc: Vienna Insurance Group / other / Vienna Insurance Group raises Group Embedded Value to more than EUR 4.5 billion

Further inquiry note: Contact: WIENER STÄDTISCHE Versicherung AG Vienna Insurance Group Barbara Hagen-Grötschnig, MBA Corporate Communications Schottenring 30, 1010 Vienna Tel.: +43 (0)50 350-21027 Fax: +43 (0)50 350 99-21027 E-Mail: b.hagen@staedtische.co.at Branche: Insurance ISIN: AT0000908504 WKN: A0ET17 ...

Fielmann AG

euro adhoc: Fielmann AG / Financial Figures/Balance Sheet / Pre-tax profit for the year: up 27 percent Dividend: up 17 percent to EUR 1.40 per share Employees: 698 additional jobs created

Further inquiry note: Ulrich Brockmann, Head of Investor Relations, tel: +49 40 270 76 - 442 Branche: Retail ISIN: DE0005772206 WKN: 577220 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Stuttgart / free trade Börse Berlin / regulated ...

intec GmbH

intec presents a flexible and economical entry-level tester for VoIP, ADSL and ISDN

Wacker Chemie AG

WACKER finalizes Acquisition of Polymer Joint Ventures

- Antitrust authorities clear takerover of APP and WPS joint ventures - Full integration into WACKER Group expected by year-end Further inquiry note: Christof Bachmair Media Relations & Information Tel. +49 89 6279-1830 E-Mail:christof.bachmair@wacker.com Branche: Chemicals ISIN: DE000WCH8881 WKN: WCH888 Index: Midcap Market Index, MDAX, CDAX, Classic All Share, HDAX, Prime All Share Börsen: Börse Frankfurt / ...

Wacker Chemie AG

WACKER to acquire Air Products' stake in construction polymers joint ventures

- Integrated value chain further strengthened - Increase in polymer sales to approx. € 1 billion in 2008 - “Another logical step in the Group’s growth strategy,” says WACKER CEO Further inquiry note: Wacker Chemie AG Corporate Communications Christof Bachmair Tel.: +49 (0) 89 6279-1830 E-Mail: christof.bachmair@wacker.com Air Products and Chemicals, Inc. ...

OMV Aktiengesellschaft

euro adhoc: OMV Aktiengesellschaft / Mergers - Acquisitions - Takeovers / Update on OMV's Declaration of Intent

Further inquiry note: OMV Investor Relations: Ana-Barbara Kuncic Tel. +43 1 40 440-21443; e-mail: investor.relations@omv.com Press: Bettina Gneisz-Al-Ani Tel. +43 1 40 440-21660; e-mail: bettina.gneisz@omv.com Thomas Huemer Tel. +43 1 40 440-21660; e-mail: thomas.huemer@omv.com Internet Homepage: ...

Boehringer Ingelheim

New Three-Year Data Confirms Aptivus(R) (tipranavir) as Effective and Durable Treatment Option for Treatment-Experienced Patients

Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...

Thielert AG

Cessna and Thielert Team to Offer Skyhawk Turbo Diesel Option

ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. air transport Hartford (USA)/Hamburg (Germany) (euro adhoc) - After an extensive market survey and flight test, Cessna Aircraft Company, a Textron Inc. (NYSE: TXT) company, announced today it will offer the Thielert (FSE: T3C) turbo diesel engine in its Skyhawk 172S aircraft with deliveries set to begin ...

Boehringer Ingelheim

Suffering in Silence - The Real Impact of the Last Taboo

Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...

Boehringer Ingelheim

Data Presented at International AIDS Society (IAS) Conference Shows Long-Term Viramune(R) (nevirapine) Efficacy and Increase in Good Cholesterol

Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...

Boehringer Ingelheim

Boehringer Ingelheim Announces First International Head-to-Head Trial of Aptivus(R) (tipranavir) versus darunavir in Treatment-Experienced HIV-Positive Patients

Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...

Boehringer Ingelheim

Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) in Diverse Group of Highly Treatment-Experienced HIV-Positive Patients

Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...

Boehringer Ingelheim

Efficacy of Boehringer Ingelheim's Pramipexole (Mirapexin(R)/Sifrol(R) Also Demonstrated in Patients With Daytime RLS Symptoms

Ingelheim Am Rhein, Germany (ots/PRNewswire) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole (Mirapexin(R)/Sifrol(R)) is also efficacious and ...

Salzgitter AG

euro adhoc: Salzgitter AG / / Publication of the Decision to Make an Offer to Acquire Securities pursuant to Section 10 para. 1 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG)

Securities Acquisition and Takeover Act announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. offeror: Company: Salzgitter Mannesmann GmbH Address: Eisenhüttenstraße 99, D-38239 Salzgitter Contact: Bernhard Kleinermann, Investor Relations Tel.: ...

Air Berlin PLC

euro adhoc: Air Berlin PLC & Co Luftverkehrs KG / Strategic management decisions / Air Berlin continues on its path to growth: Large order for 85 Boeing 737

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 28.11.2006 Berlin, November 28, 2006 - In order to be able to keep up with its European competitors in the future, Air Berlin is ordering 60 Boeing 737-800 Next Generation jets. By awarding this ...

Boehringer Ingelheim

Long-Term Data Show Aptivus(R) (tipranavir) Continues to Outperform Group of Protease Inhibitors in RESIST Trials

Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...

Boehringer Ingelheim

FDA Approves Boehringer Ingelheim's Pramipexole for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome (RLS)

Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...

Boehringer Ingelheim

Boehringer Ingelheim's pramipexole (Sifrol(R)/Mirapexin(R)) Can Provide Benefit of Improved Mood Disturbance for People With Restless Legs Syndrome

GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with ...